Tiger Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-694,600
Closed -$23.1M 48
2017
Q2
$23.1M Buy
694,600
+137,000
+25% +$4.24M 4.54% 10
2017
Q1
$17.9M Buy
557,600
+2,800
+0.5% +$95.6K 3.37% 12
2016
Q4
$20.1M Buy
+554,800
New +$22.2M 3.65% 14
2016
Q2
Sell
-356,200
Closed -$19.1M 46
2016
Q1
$19.1M Sell
356,200
-239,100
-40% -$14M 4.78% 10
2015
Q4
$39.1M Buy
+595,300
New +$36.8M 5.04% 7

Other funds holding TEVA

Tiger Management's TEVA Position: Q3 2017 in Review

Tiger Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 694,600 shares — an estimated $23.1M sold.

Tiger Management first reported a position in TEVA in Q4 2015 and held it in 5 quarters. The position peaked at $39.1M in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Tiger Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Tiger Management sold 694,600 Teva Pharmaceuticals shares in Q3 2017, an estimated $23.1M.
  • Tiger Management first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • Tiger Management's Teva Pharmaceuticals position peaked at $39.1M in Q4 2015.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Tiger Management's 13F filing for Q3 2017, filed 14 Nov 2017.